INVEST IN FIBROBIOLOGICS

The Future of Cell Therapy

FibroBiologics is a cell therapy biopharmaceutical company with over 13 years of R&D and clinical development. The company’s first product may be approved as early as 2025, alongside clinical trials for additional treatments.

This offering is for membership interest in FibroBiologics, which will own interest in the underlying company. You are not buying the underlying company's shares directly. This offering is made available through StartEngine Primary, LLC. The securities are being offered and sold only to accredited investors through general solicitation. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.